- Conditions
- Head and Neck Cancer
- Interventions
- cemiplimab+fianlimab, Cemiplimab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Thyroid Cancer
- Interventions
- Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Nonsmall Cell Lung Cancer, NSCLC
- Interventions
- NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Multiple Myeloma
- Interventions
- MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
- Biological
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Erlotinib and Dasatinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Chronic Disease
- Interventions
- Conversation Game
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Breast Cancer, Colorectal Cancer
- Interventions
- Acupuncture using Seirin® needles, Sham Acupuncture using Park Sham placebo acupuncture device
- Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Follicular Lymphoma, Tumor
- Interventions
- Obinutuzumab, CC-99282
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Interventions
- Vigil, Atezolizumab
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more
- Conditions
- Endometrial Cancer
- Interventions
- Metformin, Letrozole, Everolimus
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 6
- States / cities
- Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas
- Conditions
- Advanced Malignant Solid Neoplasm
- Interventions
- Mindfulness Relaxation, Quality-of-Life Assessment, Questionnaire Administration, Group II (mindfulness waitlist)
- Behavioral · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pheochromocytoma, Endocrine Disease, Endocrine Diseases
- Interventions
- ([18F]-DOPA), ([18F]-6F-DA)
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Years to 120 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2048
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pancreatoduodenectomy, Whipple Procedure
- Interventions
- Standard (non-antiseptic coated) suture will be used., Triclosan/antiseptic -coated suture
- Device
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Akron, Ohio • Cleveland, Ohio • Fairview, Ohio
- Conditions
- Breast Neoplasms, Breast Cancer
- Interventions
- Paclitaxel, Docetaxel, Abraxane, Ixabepilone
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 3
- States / cities
- Houston, Texas • Sugar Land, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Magrolimab, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 20
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Lymphoma, B-cell Non-Hodgkin's Lymphoma
- Interventions
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bladder Cancer
- Interventions
- N-803 and BCG, N-803
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 28
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Los Angeles, California + 25 more
- Conditions
- Cancer, Advanced, Cognitive Impairment, Mild
- Interventions
- Dyadic Life Review (DLR)
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Cancer Survivors, Informal Cancer Caregivers (Family and Friends of Cancer Survivors)
- Interventions
- Cognitively-Based Compassion Training, CHE (Cancer Health Education)
- Behavioral
- Lead sponsor
- Thaddeus Pace
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Breast Cancer
- Interventions
- Mammography Screening Conversation Aid
- Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 75 Years to 89 Years · Female only
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mammography, Breast Cancer, Radiology
- Interventions
- Search only for masses, Search only for calcifications, Search for both together, Search for one after the other
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Carcinoma
- Interventions
- Socially enhanced supervised group exercise, Exercise Intervention, Unsupervised independent exercise
- Behavioral
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 65 Years and older · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
- Interventions
- Selinexor, Ixazomib
- Drug
- Lead sponsor
- Matthew Ingham
- Other
- Eligibility
- 14 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York